Astellas Pharma and OSI Pharmaceuticals have entered into a merger agreement under which Astellas will acquire OSI for approximately $4.0 billion in cash. Astellas first launched a takeover bid for OSI in March 2010, offering $3.5 billion. The acquisition is part of Astellas’ strategy to become a global leader in oncology, a high-priority therapeutic area for Astellas. OSI focuses on the discovery, development and commercialization of molecular targeted therapies in oncology, diabetes ...